Online inquiry

IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ258MR)

This product GTTS-WQ258MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EPCAM gene. The antibody can be applied in Colon Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4072
UniProt ID P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ258MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10590MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ204MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ6180MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ1206MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ11280MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ1864MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ9319MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMP-321
GTTS-WQ967MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-323
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW